Full Press Release Details
IDEAYA Biosciences Announces US FDA IND Clearance for IDE849, a Potential First in Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors.
IDYA
IDEAYA Biosciences Announces US FDA IND Clearance for IDE849, a Potential First in Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors
Key Takeaway: IDEAYA Biosciences Announces US FDA IND Clearance for IDE849, a Potential First in Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors
Price reaction · baseline $20.47 (2025-05-05 close) · hit after-hours · clean, no other IDYA news in the window
day 0 close
-13.3%
day 1
-12.9%
day 3 · peak
-14.9%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma